

Applicants: Ron S. Israeli et al.
Serial No.: 08/470,735
Filed : June 6, 1995
Page 2

region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG.1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, which in said second antibody is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB 12492).
--

--147. (New) A kit for diagnosis, prognosis, or monitoring prostate cancer, comprising the monoclonal antibody according to claim 146 or an antigen binding fragment thereof.--

--148. (New) The kit according to claim 147 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.--

--149. (New) A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060) 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB 12492).--

--150. (New) The monoclonal antibody of claim 149, which is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB 12492).--

L
Cont

Applicants: Ron S. Israeli et al.
Serial No.: 08/470,735
Filed : June 6, 1995
Page 3

- 151. (New) A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostatic specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG.1 (SEQ ID NO:2), the antigen binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3D7-1.1 (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).--
- 152. (New) A kit for diagnosis, prognosis or monitoring prostate cancer, comprising the monoclonal antibody according to claim 151 or an antigen binding fragment thereof.--
- 153. (New) A kit according to claim 152 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.--
- 154. (New) A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).--
- 155. (New) The monoclonal antibody of claim 154, which is produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC

L
cont.

Applicants: Ron S. Israeli et al.
Serial NO.: 08/470,735
Filed : June 6, 1995
Page 4

HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).

- 156. (New) A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG.1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB 12493), and 1G9 (ATCC HB12495).--
- 157. (New) A kit for diagnosis, prognosis, or monitoring prostatic cancer, comprising the monoclonal antibody according to claim 156, or an antigen binding fragment thereof.--
- 158. (New) The kit according to claim 157 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.--
- 159. (New) A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB 12493), and 1G9 (AT HB12495).--
- 160. (New) The monoclonal antibody of claim 159, which is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB 12493),

L¹
cont.